Congo Red Free Acid

Congo Red Free Acid

SCHEMBL2583894

Nc1c(/N=N/c2ccc(-c3ccc(/N=N/c4cc(S(=O)(=O)O)c5ccccc5c4N)cc3)cc2)cc(S(=O)(=O)O)c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 1.00
ALDH1A1 P00352 2/20 1.00
THRB P10828 2/20 1.00
HPGD P15428 2/20 1.00
ALOX12 P18054 2/20 1.00
RECQL P46063 2/20 1.00
MEN1 O00255 1/20 1.00
MAPT P10636 1/20 1.00
SNCA P37840 1/20 1.00
BLM P54132 1/20 1.00
KMT2A Q03164 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
SENP2 Q9HC62 4/20 0.84
SENP1 Q9P0U3 4/20 0.84
SUMO2 P61956 3/20 0.84
SUMO1 P63165 3/20 0.84
SENP7 Q9BQF6 3/20 0.84
SLC7A11 Q9UPY5 5/20 0.79
ENPP2 Q13822 3/20 0.74
GLB1 P16278 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Congo Red Free Acid SCHEMBL29825625 1.00 APP (1.00) APPALDH1A1THRBHPGDALOX12
Congo Red Free Acid SCHEMBL29350758 1.00 APP (1.00) APPALDH1A1THRBHPGDALOX12
Congo Red Free Acid SCHEMBL1254806 1.00 APP (1.00) APPALDH1A1THRBHPGDALOX12
Congo Red Free Acid SCHEMBL17272057 0.99 APP (0.97) APPALDH1A1THRBHPGDALOX12
Congo Red Free Acid SCHEMBL5147845 0.99 APP (0.97) APPALDH1A1THRBHPGDALOX12
Congo Red Free Acid SCHEMBL29415044 0.99 APP (0.97) APPALDH1A1THRBHPGDALOX12
Congo Red Free Acid SCHEMBL326268 0.99 APP (0.97) APPALDH1A1THRBHPGDALOX12
SCHEMBL15120269 0.94 APP (0.88) APPALDH1A1THRBHPGDALOX12
SCHEMBL18044243 0.94 APP (0.88) APPALDH1A1THRBHPGDALOX12
SCHEMBL16994623 0.93 APP (0.86) APPALDH1A1THRBHPGDALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3636600-B1 A SORPTION COMPOSITION FOR COMPLEX WATER PURIFICATION EWI BVBA (BE) 2022-11-30 EP claimed
EP-3636600-A1 A SORPTION COMPOSITION FOR COMPLEX WATER PURIFICATION EWI bvba (BE) 2020-04-15 EP claimed
EP-2567225-A2 LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS Virginia Tech Intellectual Properties, Inc. (US) 2013-03-13 EP claimed
WO-2011140215-A2 LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2011-11-10 WO claimed
US-20110275558-A1 LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2011-11-10 US claimed
US-20230181744-A1 COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES FUDAN UNIVERSITY (CN) 2023-06-15 US disclosed
US-20230181744-A1 COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES FUDAN UNIVERSITY (CN) 2023-06-15 US disclosed
EP-3636600-B1 A SORPTION COMPOSITION FOR COMPLEX WATER PURIFICATION EWI BVBA (BE) 2022-11-30 EP disclosed
US-20220054500-A1 Inhibition of Thymine DNA Glycosylase in the Treatment of Cancer INSTITUT CURIE (FR) 2022-02-24 US disclosed
US-20210331122-A1 TWO-DIMENSIONAL NANOPOROUS COVALENT ORGANIC FRAMEWORK FOR SELECTIVE SEPARATION AND FILTRATION MEMBRANE FORMED THEREFROM UNIVERSITY OF WYOMING (US) 2021-10-28 US disclosed
US-20210275548-A1 NOVEL DNA POLYMERASE GAMMA INHIBITOR AND USES THEREOF ACIBADEM MEHMET ALI AYDINLAR UNIVERSITESI (TR) 2021-09-09 US disclosed
US-20210253651-A1 METHOD FOR PRODUCING ORGANIC COMPOUND-ENCAPSULATING FERRITIN AJINOMOTO CO., INC. (JP) 2021-08-19 US disclosed
US-20110275558-A1 LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2011-11-10 US disclosed
US-20100193021-A1 THIN FILM SOLAR CELL AND METHOD OF MANUFACTURING THE SAME LG DISPLAY CO., LTD. (KR) 2010-08-05 US disclosed
US-7485706-B2 Neurodegenerative protein aggregation inhibition methods and compounds THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2009-02-03 US disclosed
US-7264932-B2 Nuclease inhibitor cocktail APPLERA CORPORATION (US) 2007-09-04 US disclosed
US-7264932-B2 Nuclease inhibitor cocktail APPLERA CORPORATION (US) 2007-09-04 US disclosed
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same AMBION, INC (US) 2007-02-08 US disclosed
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same AMBION, INC (US) 2007-02-08 US disclosed
EP-0069301-A1 Process for the preparation of a polyvinyl alcohol complex compound, and the polyvinyl alcohol complex compound so prepared HOECHST AKTIENGESELLSCHAFT (DE) 1983-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181744-A1 COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES MAP1LC3B, MAP1LC3A, SQSTM1 APP 264/4885ALDH1A1 897/4885THRB 1791/4885
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same RNASE1, RNASEH1, RNASEL APP 2583/4885ALDH1A1 2603/4885THRB 3297/4885
US-20210275548-A1 NOVEL DNA POLYMERASE GAMMA INHIBITOR AND USES THEREOF POLG, POLB, POLA1 APP 3911/4885ALDH1A1 3745/4885THRB 2774/4885
US-20210253651-A1 METHOD FOR PRODUCING ORGANIC COMPOUND-ENCAPSULATING FERRITIN FTH1, HAMP, FECH APP 1199/4885ALDH1A1 3291/4885THRB 1443/4885
US-20220054500-A1 Inhibition of Thymine DNA Glycosylase in the Treatment of Cancer UNG, MPG, TYMP APP 1323/4885ALDH1A1 1403/4885THRB 1508/4885
US-20110275558-A1 LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS LANCL2, ACSL1, LANCL1 APP 4090/4885ALDH1A1 3626/4885THRB 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.